An advocacy organization that we spoke to last month characterized themselves as “neither fish nor fowl”, meaning that they do not fit into any one specific category.
It struck us immediately that this was a great way to describe our lead small molecule, RRx-001 (nibrozetone), which was originally developed as an anticancer agent but also seems to work broadly in so many other indications. These indications include radiation protection, endometriosis, cardiovascular disease, and neurodegenerative diseases like Parkinson’s Disease and ALS/MND, among others.
This broad activity is related to the bispecific mechanism of RRx-001 (nibrozetone), which protects normal tissues and harms tumors.
Three clinical trials for RRx-001 (nibrozetone) are underway/will start in 2024: a randomized Phase 3 in small cell lung cancer (SCLC), a randomized Phase 2b for prevention of severe oral mucositis in head and neck cancer, and a Phase 1 in endometriosis.
Part antioxidant, part anti-inflammatory, part nitric oxide donor, RRx-001 (nibrozetone) is neither fish nor fowl.